Liver Metastases of Noncolorectal Cancer

  • W. Timmermann
  • R. Kellersmann
  • H.-J. Gassel


Liver métastases of noncolorectal nonneuroendocrine (NCNN) carcinoma should only be resected, if radical removal can be achieved. The surgical procedure does not differ from that of colorectal métastases. The perioperative lethality ranges from o to 8.3%, the morbidity from 6 to 47%. There are no defined standard prognostic factors for patients with métastases of noncolorectal (NC) carcinoma. Patients with métastases of neuroendocrine (NE) carcinoma have a superior prognosis due to the slow progression of the underlying disease. 5 year survival rates of up to 70% have been reported after resection of those métastases. For resections of NCNN métastases 5 year survival rates up to 46% have been documented in smaller series. The value of adjuvant or neoadjuvant therapies as well as local ablative procedures has yet to be defined. The indication to resection of métastases of NC carcinoma requires careful and always individual decision.


Liver Metastasis Liver Resection Hepatic Resection Hepatic Metastasis Islet Cell Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



  1. 1.
    Raab R, Nussbaum KT, Behrend M, Weimann A (1998) Liver métastases of breast cancer: results of liver resection. Anticancer Res 18: 2231–2233PubMedGoogle Scholar
  2. 2.
    Harrison LE, Brennan MF, Newman E, Fortner JG, Picardo A, Blumgart LH, Fong Y (1997) Hepatic resection for noncolorectal, nonneuroendocrine métastases: a fifteen-year experience with ninety-six patients. Surgery 121: 625–632PubMedCrossRefGoogle Scholar
  3. 3.
    Lang H, Nussbaum KT, Weimann A, Raab R (1999) Ergebnisse der Resektion nichtcolorectaler nichtneuroendokriner Lebermetastasen. Chirurg 70: 439–446PubMedCrossRefGoogle Scholar
  4. 4.
    Zacherl M, Längle F, Steininger R, Scheuba C, Wenzl E, Jakesz R, Zacherl J (2001) Die chirurgische Therapie von nicht-kolorektalen und nichtneuroendokrinen Lebermetastasen. Wien Klin Wochenschr 113:681–687PubMedGoogle Scholar
  5. 5.
    Hemming AW, Sielaff TD, Gallinger S, Cattral MS, Taylor BR, Greig PD, Langer B (2000) Hepatic resection of noncolorectal nonneuroendocrine métastases. Liver Transpl 6: 97–101PubMedGoogle Scholar
  6. 6.
    Lindeil G, Ohlsson B, Saarela A, Andersson R, Tranberg KG (1998) Liver resection of noncolorectal secondaries. J Surg Oncol 69: 66–70CrossRefGoogle Scholar
  7. 7.
    van Ruth S, Mutsaerts E, Zoetmulder FA, van Coevorden F (2001) Metastasectomy for liver metastases of non-colorectal primaries. Eur J Surg Oncol 27: 662–667PubMedCrossRefGoogle Scholar
  8. 8.
    Bines SD, England G, Deziel DJ, Witt TR, Doolas A, Roseman DL (1993) Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 114: 799–805PubMedGoogle Scholar
  9. 9.
    Elias D, Cavalcantid A, Eggenspieler P et al. (1998) Resection of liver métastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 187: 487–493PubMedCrossRefGoogle Scholar
  10. 10.
    Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36–42PubMedCrossRefGoogle Scholar
  11. 11.
    Lehnert T (1998) Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 66: 1307–1312PubMedCrossRefGoogle Scholar
  12. 12.
    Laurent C, Rullier E, Feyler A, Masson B, Saric J (2001) Resection of noncolorectal and nonneuroendocrine liver metastases: late metastases are the only chance of cure. World J Surg 25: 1532–1536PubMedGoogle Scholar


  1. 1.
    Hogan BA, Thornton FJ, Brannigan M, Browne TJ, Pender S, O’Kelly P, Lyon SM, Lee MJ (2002) Hepatic métastases from an unknwon primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations. Clin Radiol 57:1073–1077PubMedCrossRefGoogle Scholar
  2. 2.
    Kliche KO, Kubsch K, Raida M, Masri-Zada R, Hoffken K (2002) Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine; The Jena experience in 79 patients. J Cancer Res Clin Oncol 128:516–524PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • W. Timmermann
    • 1
  • R. Kellersmann
    • 2
  • H.-J. Gassel
    • 3
  1. 1.Bayerische Julius-Maximilians-Universität, Chirurgische UniversitätsklinikWürzburgGermany
  2. 2.Bayerische Julius-Maximilians-Universität, Klinik und Poliklinik für ChirurgieWürzburgGermany
  3. 3.Bayerische Julius-Maximilians-Universität, Chirurgische UniversitätsklinikWürzburgGermany

Personalised recommendations